英国生物样本库中精神分裂症的遗传与表型特征
这项横断面研究比较了英国生物样本库中1438例精神分裂症患者与临床招募样本的遗传负荷和表型特征。英国生物样本库患者的精神分裂症多基因风险评分显著低于3个临床样本,精神分裂症相关拷贝数变异率显著低于CLOZUK样本,且教育程度和就业率更高、吸烟率更低、精神病起病年龄更晚。提示志愿者生物样本库中的精神分裂症患者代表病情较轻的人群。
要点
- 英国生物样本库精神分裂症患者的精神分裂症多基因风险评分显著低于3个临床样本。
- 英国生物样本库患者精神分裂症相关拷贝数变异率显著低于CLOZUK样本。
- 英国生物样本库患者教育程度和就业率更高、吸烟率更低、起病年龄更晚。
核心结论
- 英国生物样本库中的精神分裂症患者代表病情较轻的人群,纳入更广泛研究可增强对疾病严重度全谱的代表性。
研究设计与样本
- 数据收集于1993年1月至2021年7月,分析于2021年7月至2023年6月。
- 对英国生物样本库精神分裂症病例对照状态进行全基因组关联研究,并通过遗传相关性与PGC结果比较。
- 使用PRS-CS计算精神分裂症、双相障碍、抑郁和智力的多基因风险评分,采用成对逻辑回归比较PRS和表型,采用Firth逻辑回归比较精神分裂症相关拷贝数变异比例。
主要发现
- 英国生物样本库中精神分裂症易感性与PGC最新全基因组关联研究的遗传相关性为0.98(SE=0.18)。
- 精神分裂症PRS解释了英国生物样本库中精神分裂症病例状态6.8%的方差。
- 英国生物样本库精神分裂症患者的精神分裂症PRS显著低于3个临床样本,精神分裂症相关拷贝数变异率显著低于CLOZUK样本。
- 英国生物样本库精神分裂症患者教育程度和就业率高于临床样本,吸烟率更低,精神病起病年龄更晚。
临床怎么用
- 解读生物样本库来源的精神分裂症遗传研究时,需注意志愿者偏倚可能导致患者病情较轻。
- 将生物样本库与临床样本结合可更全面反映精神分裂症的严重度谱系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Large-scale biobanks provide important opportunities for mental health research, but selection biases raise questions regarding the comparability of individuals with those in clinical research settings. OBJECTIVE: To compare the genetic liability to psychiatric disorders in individuals with schizophrenia in the UK Biobank with individuals in the Psychiatric Genomics Consortium (PGC) and to compare genetic liability and phenotypic features with participants recruited from clinical settings. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study included participants from the population-based UK Biobank and schizophrenia samples recruited from clinical settings (CLOZUK, CardiffCOGS, Cardiff F-Series, and Cardiff Affected Sib-Pairs). Data were collected between January 1993 and July 2021. Data analysis was conducted between July 2021 and June 2023. MAIN OUTCOMES AND MEASURES: A genome-wide association study of UK Biobank schizophrenia case-control status was conducted, and the results were compared with those from the PGC via genetic correlations. To test for differences with the clinical samples, polygenic risk scores (PRS) were calculated for schizophrenia, bipolar disorder, depression, and intelligence using PRS-CS. PRS and phenotypic comparisons were conducted using pairwise logistic regressions. The proportions of individuals with copy number variants associated with schizophrenia were compared using Firth logistic regression. RESULTS: The sample of 517 375 participants included 1438 UK Biobank participants with schizophrenia (550 [38.2%] female; mean [SD] age, 54.7 [8.3] years), 499 475 UK Biobank controls (271 884 [54.4%] female; mean [SD] age, 56.5 [8.1] years), and 4 schizophrenia research samples (4758 [28.9%] female; mean [SD] age, 38.2 [21.0] years). Liability to schizophrenia in UK Biobank was highly correlated with the latest genome-wide association study from the PGC (genetic correlation, 0.98; SE, 0.18) and showed the expected patterns of correlations with other psychiatric disorders. The schizophrenia PRS explained 6.8% of the variance in liability for schizophrenia case status in UK Biobank. UK Biobank participants with schizophrenia had significantly lower schizophrenia PRS than 3 of the clinically ascertained samples and significantly lower rates of schizophrenia-associated copy number variants than the CLOZUK sample. UK Biobank participants with schizophrenia had higher educational attainment and employment rates than the clinically ascertained schizophrenia samples, lower rates of smoking, and a later age of onset of psychosis. CONCLUSIONS AND RELEVANCE: Individuals with schizophrenia in the UK Biobank, and likely other volunteer-based biobanks, represent those less severely affected. Their inclusion in wider studies should enhance the representation of the full spectrum of illness severity.
引用
- Legge SE, Pardiñas AF, Woolway G, et al. Genetic and Phenotypic Features of Schizophrenia in the UK Biobank. JAMA Psychiatry. 2024. PMID: 38536179. doi:10.1001/jamapsychiatry.2024.0200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。